Information Journal Paper
APA:
Copy. (2020). Subcutaneous tocilizumab in adults with severe and critical COVID-19: A prospective open-label uncontrolled multicenter trial. INTERNATIONAL JOURNAL OF IMMUNOPHARMACOLOGY, -(-), 0-0. SID. https://sid.ir/paper/701824/en
Vancouver:
Copy. Subcutaneous tocilizumab in adults with severe and critical COVID-19: A prospective open-label uncontrolled multicenter trial. INTERNATIONAL JOURNAL OF IMMUNOPHARMACOLOGY[Internet]. 2020;-(-):0-0. Available from: https://sid.ir/paper/701824/en
IEEE:
Copy, “Subcutaneous tocilizumab in adults with severe and critical COVID-19: A prospective open-label uncontrolled multicenter trial,” INTERNATIONAL JOURNAL OF IMMUNOPHARMACOLOGY, vol. -, no. -, pp. 0–0, 2020, [Online]. Available: https://sid.ir/paper/701824/en